NCT-501

Overview

NCT-501 is a reversible, non-competitive, selective, blood-brain barrier-permeable ALDH1A1 inhibitor with an IC 50 of 40 nM. NCT-501 inhibits the AKT-β-catenin signaling pathway, induces necroptosis in nasopharyngeal carcinoma cells, suppresses their proliferation and inhibits stem cell spheroid formation. NCT-501 can be used in research related to nasopharyngeal carcinoma, esophageal squamous cell carcinoma and malignant tumors.

Application

Products | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Nasopharyngeal Cancer | Products > Disease Areas > Esophageal Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Aldehyde Dehydrogenase (ALDH) | Products > Signaling Pathways > Akt | Products > Signaling Pathways > β-catenin | Products > Signaling Pathways > Necroptosis

Product Information

• Catalog No.: HY-18768
• CAS No.: 1802088-50-1
• Molecular Formula: C21H32N6O3
• Molecular Weight: 416.52
• Purity: 99.59%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 1.25 mg/mL (3.00 mM); Clear solution
• Availability: In-stock

Source

Original product source